Faster, Smaller, Smarter: Intelligent Manufacturing Of mRNA Through The Power Of Process Analytical Technologies

The field of RNA-based therapeutics and vaccines is rapidly expanding, encompassing novel treatments, cancer vaccines, protein replacement, and gene editing approaches. To sustain this momentum, manufacturing technology mustn't become a bottleneck, hindering innovation and progress. Process analytical technologies (PAT) play a crucial role in addressing this challenge by enabling real-time measurement and control of production processes, ensuring product quality, and accelerating development timelines. Inline analytics can replace the widespread reliance on offline assays, which often slow down traditional batch manufacturing.

ReciBioPharm (RBP), a leader in the ATMP CDMO space, has received an award from MIT to collaborate on a fully integrated, digitally controlled xRNA manufacturing process. This groundbreaking initiative aims to reduce development timelines from 9–12 months to just 2–4 months while condensing cGMP manufacturing — from in vitro transcription (IVT) to fill-finish — into a single day. By leveraging a powerful platform that integrates cutting-edge PAT and inline analytics, RBP is developing predictive models that allow real-time monitoring of critical quality attributes (CQAs).

Watch this webinar to explore the transformative potential of PAT in mRNA manufacturing, including how predictive models monitor key CQAs like RNA concentration and nucleoside triphosphate consumption. Gain insights into RBP and MIT’s vision for revolutionizing biomanufacturing and the advantages of integrating PAT for more efficient, continuous production within a streamlined digital infrastructure.